Study of YH42946 for advanced cancer with HER2 or EGFR changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic cancer that has progressed after standard treatments, or where standard treatment is not appropriate.
- Your tumor must have a specific HER2 alteration or EGFR mutation (confirmed by a tumor sample).
- You must be in good physical condition (able to carry out daily activities).
- Your liver, kidney, and bone marrow function must be adequate.
- If you have brain metastases, they must have been treated and be stable.
- You must not have untreated or progressing brain metastases, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
This trial tests a new drug called YL-17231 in people with advanced solid tumors that have specific changes (mutations) in the KRAS, HRAS, or NRAS genes. It is for patients whose cancer has stopped responding to or cannot tolerate standard treatments.
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
This trial tests a new drug called SYH2095 for people with advanced solid tumors, including a specific type of breast cancer (HR+/HER2-). The goal is to see if it is safe and effective. You may join if you are an adult with a tumor that can be measured and you are in generally good health.
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.